Scynexis: SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update

SCYNEXIS announced an exclusive license agreement with GSK plc (LSE/NYSE: GSK) for the global rights to develop and commercialize BREXAFEMME® (ibrexafungerp tablets). SCYNEXIS will receive an upfront payment

Related Keywords

Denmark ,Jersey ,Copenhagen ,Køavn ,David Angulo ,Debbie Etchison ,Irina Koffler ,Triterpenoid Antifungals ,Exchange Commission ,Scynexis Inc ,European Congress ,Nasdaq ,Drug Administration ,Chief Executive Officer ,License Agreement ,Scientific Presentations ,Annual European Congress ,Clinical Microbiology ,Infectious Diseases ,Medical Affairs ,Private Securities Litigation Reform Act ,Annual Report ,Months Ended March ,Gefallene Big Techs ,Scynexis ,Nnounces ,First ,Quarter ,023 ,Financial ,Results ,Rovides ,Corporate ,Update ,